Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 3,033,296,524 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 3,033,296,524 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 0 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 3,033,296,524 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 511,844,582 | 561,378,936 | 604,363,420 | 629,412,126 | 726,297,460 | 3,033,296,524 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 9,251,603 | 9,629,978 | 101,304,972 | 52,614,894 | 113,415,703 | 286,217,150 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 17,212,855 | 23,432,437 | 14,052,058 | 14,915,439 | 7,706,225 | 77,319,014 |
| 11 | Total support. Add lines 7 through 10 | 3,397,140,821 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2016 | (b) 2017 | (c) 2018 | (d) 2019 | (e) 2020 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2020 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2020 |
(iii) Distributable Amount for 2020 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2020 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2019 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2020: | ||||
| a From 2015....... | ||||
| b From 2016....... | ||||
| c From 2017....... | ||||
| d From 2018....... | ||||
| e From 2019....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2020 distributable amount | ||||
|
i
Carryover from 2015 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2020 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2020 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2020, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2020. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2021. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2016..... | ||||
| b Excess from 2017..... | ||||
| c Excess from 2018..... | ||||
| d Excess from 2019..... | ||||
| e Excess from 2020..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| FORM 990, PART I, LINE 1 | THE MISSION OF DANA-FARBER CANCER INSTITUTE, INC. (DFCI) IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. FORM 990, PART III, LINE 1 The Mission of DFCI is to provide expert, compassionate, and equitable care to children, adults, and their families, while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. We train new generations of clinicians and scientists, disseminate innovative patient therapies and scientific discoveries around the world, and reduce the impact of cancer, while at all times maintaining a focus on those communities who have been historically marginalized. FORM 990, PART III, LINE 4A CLINICAL CARE As one of the leading cancer centers in the world, DFCI provides compassionate, comprehensive, and personalized care to adults and children with cancer, blood disorders, and related diseases. In fiscal year 2021, our expert clinicians and caregivers at our specialized treatment centers worked together to deliver the latest therapies to our patients through 1,436 inpatient admissions, 364,577 outpatient MD visits, and 188,242 infusion treatments. Since its founding in 1947 by Sidney Farber, MD, Dana-Farber has followed his vision for a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Dana-Farber is a founding member of Dana-Farber/Harvard Cancer Center and one of 51 NCI-designated Comprehensive Cancer Centers in the UNITED STATES. Dana-Farber is the only hospital ranked in the top four nationally by U.S. News and World Report in both adult and pediatric cancer care. In 2021, we offered more than 1,100 clinical trials. FORM 990, PART III, LINE 4B RESEARCH Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity's greatest health challenges. Some recent advances include: Immunotherapy Combination Found Effective in Non-small Cell Lung Cancer: A combination of two drugs that open the floodgates to an immune system attack on cancer curtailed tumor growth in some patients with non-small cell lung cancer that was resistant to a single immunotherapy agent, A CLINICAL TRIAL LED BY DANA-FARBER INVESTIGATORS SHOWED. Cellular Source of Barrett's Esophagus Identified: In two studies, Dana-Farber scientists demonstrated that Barrett's esophagus - a potential precursor of esophageal adenocarcinoma - does not involve esophageal cells turning into intestinal cells, as had long been thought, but of stomach cells adopting some of the characteristics of intestinal cells. Immunotherapy Combination Found Beneficial in Advanced Melanoma: A combination of two drugs that target different proteins on immune system T cells kept advanced melanoma in check significantly longer than one of the drugs alone in a clinical trial co-led by Dana-Farber scientists. Drug Combination Can Keep Chronic Leukemia in Remission in Young Patients: Young patients with chronic lymphocytic leukemia can enjoy long remissions on the drug ibrutinib and chemotherapy, but must stay on ibrutinib indefinitely to keep the cancer in remission, Dana-Farber researchers found in a clinical trial. Vaccination Protects Against COVID-19 in Patients with Myeloma: For patients with multiple myeloma, vaccination against COVID-19 provides some protection against coronavirus infection, but to a far lower degree than the general population of cancer survivors, Dana-Farber investigators found. Targeted Drug Combination Shows Unprecedented Activity in Some Brain Tumors: A combination of two targeted cancer drugs - dabrafenib and trametinib - showed unprecedented, "clinically meaningful" activity in patients with highly malignant brain tumors that carried a rare genetic mutation, a clinical trial led by Dana-Farber investigators showed. Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants: Dana-Farber researchers found that in most cases, stem cell transplants from donors with clonal hematopoiesis, an asymptomatic blood condition, are safe and effective. Venetoclax Can Benefit Patients with Waldenstrom Macroglobulinemia: In a clinical trial led by Dana-Farber investigators, more than 80% of patients with Waldenstrom macroglobulinemia had a "major" response to a two-year course of the drug venetoclax with generally manageable side effects. Older and Younger Patients with Metastatic Colorectal Cancer Have Similar Survival: Even though young patients with metastatic colorectal cancer tend to be more fit and receive more intensive treatment than older patients, both groups survive for roughly the same amount of time, Dana-Farber researchers reported. Young Women Who Undergo Mastectomy Report Lower Quality of Life: Even as more young women with breast cancer opt to have mastectomies, many experience a persistent decline in their sexual and psychosocial well-being following the procedure, research by Dana-Farber investigators shows. Antibody-Drug Conjugate Impressive in Patients with a Form of Non-small Cell Lung Cancer: In an international clinical trial led by Dana-Farber investigators, more than half of patients with non-small cell lung cancer harboring a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug consisting of a chemotherapy agent linked to an antibody. Vitamin D May Protect Against Young-Onset Colorectal Cancer: Consuming higher amounts of Vitamin D - mainly from dietary sources - may help protect against developing young-onset colorectal cancer or precancerous colon polyps, researchers at Dana-Farber and other institutions reported in the first study to show such an association. Pain Management Worsening for Patients with Terminal Cancer: In a sign that pain management for patients dying of cancer is worsening, a study by Dana-Farber investigators found a sharp decline in opioid access among these patients over a recent 10-year period, even as many more of them turned to hospital emergency rooms for pain treatment. Cancer Screenings Rebounded After COVID-related Decline: The numbers of cancer screening tests rebounded sharply in the last quarter of 2020, following a dramatic decline in the first months of the COVID-19 pandemic, at one large hospital system in the Northeastern United States, a study by Dana-Farber researchers showed. Antibiotic Found to Kill Tumor Cells with DNA-repair Glitch: Novobiocin, an antibiotic developed in the 1950s and largely supplanted by newer drugs, effectively targets, and kills cancer cells with a common genetic defect, research by Dana-Farber scientists showed. The findings spurred investigators to open a clinical trial of the drug for patients whose tumors carry the abnormality. Red Meat Consumption May Promote DNA Damage Associated with Colorectal Cancer: Genetic mutations indicative of DNA damage were associated with high red meat consumption, and increased cancer-related mortality in patients with colorectal cancer, a study led by Dana-Farber researchers found. Immunotherapy Drug Delays Kidney Cancer Recurrence: Treatment with the immunotherapy drug pembrolizumab after kidney cancer surgery prolonged the period in which patients lived without a recurrence of the cancer among patients at high risk of such recurrence, Dana-Farber researchers found. Level of Chromosomal Abnormality in Non-small Cell Lung Cancer May Predict Response to Immunotherapy: Patients with non-small cell lung cancer whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber researchers reported. New Targeted Drug Shown Effective in Patients with a Form of Uterine Cancer: In its first clinical trial in patients with uterine serous carcinoma, a hard-to-treat form of uterine cancer, the targeted drug adavosertib, which subjects tumor cells to extensive DNA damage caused tumors to shrink in nearly one-third of patients, Dana-Farber investigators reported. |
| FORM 990, PART III, LINE 4C | COMMUNITY BENEFITS The role of Dana-Farber's Community Benefits Office is to support the institute's goal to reduce cancer risk among medically underserved populations. To that end, we work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancer control. We are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, skin, and prostate cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening, and clinical trials; and strengthen the support system for medically underserved populations. In short, we are committed to making Dana-Farber's care and research findings more accessible to everyone within and outside its walls. In FY 2021: A total of 1,512 individuals were reached overall through 17 community education, outreach, and screening events. program volumes have continued to be impacted by the covid-19 pandemic. The Community Benefits Office has continued to pivot to adapt to challenges related to the ongoing COVID-19 pandemic. In particular, the Community Benefits Office has continued to provide education virtually by leveraging the online platforms of community partners such as Union Capital Boston. In addition, Dana-Farber worked closely with an allocations committee to launch the Institute's determination of need community health initiative funding process virtually. Through this process, Dana-Farber awarded the first round of funding for its access to services awards, aimed at ensuring all residents, particularly those at higher risk for developing cancer and other chronic conditions, have access to coordinated and equitable health and support services. Programmatic highlights are as follows: Dana-Farber's mammography services provided 1,774 mammograms in the van and at the mammography suite at Whittier Street Health Center in Roxbury. Dana-Farber's Sun Safety program developed a COVID-19 protocol to ensure that adequate health and safety measures were followed at each screening event. In FY 2021, 11 in-person sun safety screening events were held with added health and safety measures and approval from local health departments. 484 participants were screened by a dermatologist and 133 people were referred for follow-up appointments. 65 participants were referred for a biopsy. The majority of biopsy recommendations were due to a presumptive diagnosis of basal cell carcinoma, squamous cell carcinoma or melanoma. The Tobacco Treatment program received 96 referrals and provided 125 individual tobacco cessation counseling sessions to 41 patients. 36 participants were able to reduce their total number of cigarettes smoked per day, and 10 of these reported being able to quit completely. In FY21 the Tobacco Treatment program received a grant from Friends of Dana-Farber Cancer Institute. The funds were used to provide financial incentives for patients enrolled in the smoking cessation program to encourage individuals to reduce their tobacco usage and quit smoking. Dana-Farber continues to partner with Team Maureen to lead the statewide Massachusetts HPV Coalition. This year, the Coalition's oral HPV task force launched the second edition of their dental toolkit for providers and patients in 7 languages. Dana-Farber also continues to play a leading role in the Annual HPV-Related Cancer Summit. Approximately 105 medical and dental providers, public health professionals, and community advocates attended the FY21 summit on the latest HPV research and best practices. Dana-Farber awarded the first round of funding for its access to services grants to 12 nonprofit organizations in Greater Boston to support long-lasting community health improvement and boost linkages to existing health and support services in the region. Dana-Farber committed approximately $1 million dollars to the healthy neighborhoods equity fund to address housing needs in Greater Boston. Dana-Farber partnered with Union Capital Boston and the Dana-Farber/Harvard Cancer Center to host 4 cancer awareness resource nights focused on breast and colorectal cancer screening, the HPV vaccine, cancer clinical trials, and cancer survivorship, engaging over 800 community residents virtually. These events featured an education session on a cancer-related topic, survivor testimony, and Q&A sessions with audience members. Dana-Farber launched a new partnership with myhealthfair.org to increase virtual education and outreach with the local Spanish-speaking community. In FY21, Dana-Farber was able to provide video and written educational materials, as well as promote sun safety and mammography van events. FORM 990, PART VI, SECTION A, LINE 2 FAMILY OR BUSINESS RELATIONSHIP FAMILY RELATIONSHIP: JOHN O'CONNOR AND LAURA SEN BUSINESS RELATIONSHIP: RICHARD LUBIN, CHRISTOPHER HADLEY, AND JANE BROCK-WILSON BUSINESS RELATIONSHIP: JOSH BEKENSTEIN, ANDREW KAPLAN, AND NANCY LOTANE BUSINESS RELATIONSHIP: PHILLIP GROSS AND DEMOND MARTIN Business Relationship: Andrew Janower And Michael Eisenson Form 990, Part VI, SECTION B, Line 11B PROCESS USED TO REVIEW THE FORM 990 THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. |
| FORM 990, PART VI, SECTION B, LINE 12C | MONITORING & ENFORCEMENT OF CONFLICT OF INTEREST POLICY DFCI MONITORS AND ENFORCES COMPLIANCE WITH THE DFCI CONFLICT-OF-INTEREST POLICIES FOR BOARD OFFICERS, TRUSTEES, AND KEY EMPLOYEES ("COVERED PERSONS"). THE OFFICE OF THE GENERAL COUNSEL ANNUALLY DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE AND CONFIDENTIALITY STATEMENT REQUIRING ALL COVERED PERSONS TO DISCLOSE INTERESTS, ROLES, AND ACTIVITIES THAT COULD GIVE RISE TO A POTENTIAL OR ACTUAL CONFLICT WITH THE INTERESTS OF DFCI. IF A TRUSTEE FAILS TO COMPLETE THE ANNUAL STATEMENT, THE CHAIR OF THE GOVERNANCE COMMITTEE MAY TAKE ACTIONS TO SUSPEND THE TRUSTEE OR CAUSE REMOVAL. DFCI REQUIRES COVERED PERSONS TO COMPLETE THE STATEMENT UPON INITIAL APPOINTMENT TO A COVERED OFFICE AND TO UPDATE THEIR DISCLOSURES ON A CONTINUING BASIS WHENEVER A COVERED PERSON BECOMES AWARE OF A NEW OR PREVIOUSLY UNDISCLOSED INTEREST. THE OFFICE OF GENERAL COUNSEL COMPARES THE DISCLOSURES TO INSTITUTIONAL INFORMATION IN ORDER TO IDENTIFY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. THE GOVERNANCE COMMITTEE OF THE DFCI BOARD OF TRUSTEES REVIEWS DISCLOSURES AND WORKS WITH THE GENERAL COUNSEL TO ADDRESS ISSUES THAT MAY ARISE. THE GOVERNANCE COMMITTEE IS RESPONSIBLE TO BRING MAJOR ISSUES RELATED TO THE CONFLICT OF INTEREST POLICY TO THE EXECUTIVE COMMITTEE AND THE ENTIRE BOARD IF DEEMED NECESSARY. THE BOARD'S CONFLICTS OF INTEREST OVERSIGHT COMMITTEE REVIEWS AND, WHEN APPROPRIATE, INSTITUTES WRITTEN MANAGEMENT PLANS TO MANAGE CONFLICTS OF INTEREST PRESENTED BY INTERESTS OF CERTAIN EXECUTIVE OFFICERS AND CERTAIN TRUSTEE INVESTMENT INTERESTS. A PROPOSED ARRANGEMENT CREATING A CONFLICT OF INTEREST MAY BE APPROVED IF APPROPRIATE STEPS ARE TAKEN TO ENSURE THAT DFCI MAKES A DECISION IN AN OBJECTIVE AND FAIR MANNER CONSISTENT WITH THE HIGHEST ETHICAL AND LEGAL STANDARDS. SUCH STEPS INCLUDE RECUSAL OF THE COVERED PERSON WITH A CONFLICT OF INTEREST FROM NEGOTIATIONS OR DISCUSSIONS ON BEHALF OF DFCI OR THE ENTITY WITH WHICH DFCI IS DOING BUSINESS AND FROM BOARD OR DFCI MANAGEMENT DISCUSSIONS OF SUCH ARRANGEMENT. |
| FORM 990, PART VI, SECTION B, LINE 15A | PROCESS FOR DETERMINING COMPENSATION OF PRESIDENT PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE BI-ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. |
| FORM 990, PART VI, SECTION B, LINE 15B | PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE BI-ANNUALLY RECEIVES THE REPORT OF AN INDEPENDENT REVIEW BY A THIRD PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE APPROVAL OF THE COMPENSATION COMMITTEE IS REPORTED TO THE EXECUTIVE COMMITTEE OF THE BOARD OF TRUSTEES AND TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF SEPTEMBER 2020. |
| FORM 990, PART VI, SECTION C, LINE 19 | AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS TO THE PUBLIC. GOVERNING DOCUMENTS THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THE GOVERNING DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2016 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. ANNUAL AUDITED FINANCIAL STATEMENTS FROM FISCAL YEAR 1998 THROUGH FISCAL YEAR 2015 ARE AVAILABLE UPON REQUEST. |
| FORM 990, PART VII, SECTION B, LINE 1 | THE AMOUNT PAID TO WALSH BROTHERS, INC. INCLUDED COSTS FOR BUILDING SERVICES AND MATERIALS. HOWEVER, THE ORGANIZATION WAS UNABLE TO OBTAIN INFORMATION TO BREAKOUT THE EXACT AMOUNT FOR MATERIAL COSTS. |
| FORM 990, PART XI, LINE 9 | OTHER CHANGES IN NET ASSETS CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES $ 576,115,403 CHANGE IN VALUE OF SWAP AGREEMENT $ 13,721,943 PENSION ADJUSTMENT $ 7,027,782 ---------------------- TOTAL OTHER CHANGES IN NET ASSETS $ 596,865,128 |
| Software ID: | |
| Software Version: |